We discovered that treating cancer cells with PTX causes them to generate a specific class of EVs, namely exosomes, that are uniquely enriched with Survivin, a protein whose expression is tightly correlated with poor patient prognosis, chemotherapy resistance, and tumor recurrence. Here, BIRC5 is linked to neoplasm.